- Home
- APVO vs ENVB Comparison
APVO vs ENVB Comparison
Compare APVO & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- ENVB
- Stock Information
- Founded
- APVO 2016
- ENVB 1994
- Country
- APVO United States
- ENVB United States
- Employees
- APVO N/A
- ENVB N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- ENVB Health Care
- Exchange
- APVO Nasdaq
- ENVB Nasdaq
- Market Cap
- APVO 3.7M
- ENVB 4.2M
- IPO Year
- APVO N/A
- ENVB N/A
- Fundamental
- Price
- APVO $0.21
- ENVB $0.37
- Analyst Decision
- APVO Strong Buy
- ENVB Strong Buy
- Analyst Count
- APVO 1
- ENVB 1
- Target Price
- APVO $8.00
- ENVB $10.00
- AVG Volume (30 Days)
- APVO 17.5M
- ENVB 346.2K
- Earning Date
- APVO 11-07-2024
- ENVB 11-14-2024
- Dividend Yield
- APVO N/A
- ENVB N/A
- EPS Growth
- APVO N/A
- ENVB N/A
- EPS
- APVO N/A
- ENVB N/A
- Revenue
- APVO N/A
- ENVB N/A
- Revenue This Year
- APVO N/A
- ENVB N/A
- Revenue Next Year
- APVO N/A
- ENVB N/A
- P/E Ratio
- APVO N/A
- ENVB N/A
- Revenue Growth
- APVO N/A
- ENVB N/A
- 52 Week Low
- APVO $0.14
- ENVB $0.36
- 52 Week High
- APVO $10.80
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- APVO 43.68
- ENVB 29.99
- Support Level
- APVO $0.24
- ENVB $0.45
- Resistance Level
- APVO $0.33
- ENVB $0.52
- Average True Range (ATR)
- APVO 0.04
- ENVB 0.05
- MACD
- APVO -0.01
- ENVB -0.01
- Stochastic Oscillator
- APVO 0.70
- ENVB 4.44
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.